Adverse events that occurred more frequently with LY2951742 than with placebo included injection site pain , erythema , or both ( 21 [ 20 % ] of 107 vs seven [ 6 % ] of 110 ) , upper respiratory tract infections ( 18 [ 17 % ] vs ten [ 9 % ] ) , and abdominal pain ( six [ 6 % ] vs three [ 3 % ] ) .